No user image
Nicola Ambler Oct 08
advanced therapy manufacturing shortage webinar Phacilitate

[WEBINAR] Overcoming the shortages in cell and gene therapy manufacturing capacity; a global problem with local consequences

A panel of advanced therapy manufacturing experts explore strategies to overcome the global manufacturing shortage
There is no doubt about the strength of the advanced therapy pipeline, with more approvals predicted to grow exponentially in the coming years. However, ensuring sufficient global manufacturing capacity and a robust infrastructure to deliver therapies at scale and where they're needed are absolutely crucial to the successful commercialisation of these therapies.
This was the topic of a vibrant plenary panel discussion at Phacilitate Leaders Europe last month, which could have gone on for hours. As you might expect, the panel was inundated with questions from the audience and not all were able to be covered.

So, we’ve brought the panel back together to dive straight into these six questions:

1) Apart from shortages in manufacturing capacity, do you expect shortages in materials, e.g. consumables, cell culture media, other reagents?

2) Within manufacturing, could we increase the capacity of unit operations and simultaneous operation of batches to accommodate patient population?

3) What happens when we get approval for a large indication like solid tumours or diabetes?

4) What is the single biggest limiting factor in the current manufacturing process that could be solved with automation?

5) Can we make use of already existing infrastructure and if yes, how?

6) What other industries do you look at to model for building the manufacturing scale ‘with agility’?


Date: October 31st 2019
Time: 4pm BST | 12pm EST 
How: register here

David Landowski, Brooks Automation

Moderator: Anthony Davies, Founder and CEO
Dark Horse Consulting

Cenk sumen, CTO, Stemson Therapeutics

Cenk Sumen, Chief Technology Officer
Stemson Therapeutics

Troels Jordansen, CEO

James Miskin, Oxford Biomedica

James Miskin, CTO
Oxford Biomedica

The webinar will be available on-demand so if you can't make the live session, register your details and we'll send you the recording.